Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198012 | 0.91 | HTT (0.42) | HTTFURINBACE1SIRT2SIRT1 | |
| SCHEMBL31713913 | 0.88 | FURIN (0.44) | HTTFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL16801698 | 0.87 | FURIN (0.39) | HTTFURINSIRT5SMN1; SMN2 | |
| SCHEMBL12094324 | 0.86 | FURIN (0.39) | HTTFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL23286090 | 0.86 | HTT (0.41) | HTTFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL13814439 | 0.86 | SIRT2 (0.55) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22387920 | 0.86 | SIRT2 (0.55) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17312925 | 0.86 | FURIN (0.39) | HTTFURINSMN1; SMN2 | |
| SCHEMBL23680473 | 0.85 | HTT (0.40) | HTTFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL22283146 | 0.85 | SIRT2 (0.40) | BACE1SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4570837-A1 | POLYMER CONTRAST AGENT | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2024-08-08 | — | — | US | disclosed |
| WO-2024150132-A1 | LIGAND-DRUG CONJUGATES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2024-07-18 | — | — | WO | disclosed |
| EP-4362982-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | Byondis B.V. (NL) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275025-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041776-A1 | POLYMER CONTRAST AGENT | RXFP3, HAX1, MSR1 | HTT 2576/4885FURIN 3777/4885BACE1 4058/4885 |
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | CD47, PTMS, PAG1 | HTT 3683/4885FURIN 487/4885BACE1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.